Accueil > Publications > Recherche par années > Années 1990 > 1998

Masse, A ; Ramirez, LH ; Bindoula, G ; Grillon, C ; Wdzieczak-Bakala, J ; Raddassi, K ; Deschamps De Paillette, E ; Mencia-Huerta, JM ; Potier, P ; Sainteny, F ; Carde, P

The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity : improvement in mice survival and protection of bone marrow stem cells and progenitors.

Blood 91(2) 441-449

par Administrateur - publié le

Abstract :

The tetrapeptide Acetyl-N-Ser-Asp-Lys-Pro (AcSDKP or Goralatide), a physiological regulator of hematopoiesis, inhibits the entry into the S-phase of murine and human hematopoietic stem cells. It has been shown to reduce the damage to specific compartments in the bone marrow resulting from treatment with chemotherapeutic agents, ionizing radiations, hyperthermy, or phototherapy. The present study was performed to assess the therapeutic potential of AcSDKP in vivo in reducing both the toxicity and the hematopoietic damage induced by fractionated administration of doxorubicin (DOX), a widely used anticancer drug. Here we showed that AcSDKP could reduce COX-induced mortality in mice and could protect particularly the long-term reconstituting cells (LTRCs) in addition to colony forming units-spleen, high proliferative potential colony-forming cells, and colony-forming units-granulocyte-macrophage (CFU-GM) from DOX toxicity.